Market Newsdesk

NEW YORK, Feb. 17, 2021 /PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) from May 11, 2020 through November 4, 2020(the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934.

If you purchased bluebird securities, and/or would like to discuss your legal rights and options please visit BLUE Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) data supporting bluebird’s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On November 4, 2020, post-market, bluebird disclosed that it would no longer apply for FDA approval of its LentiGlobin product as a treatment for SCD in the second half of 2021 as expected. Instead, citing “feedback” from the FDA requiring the Company to provide additional data “to demonstrate drug product comparability” for LentiGlobin for SCD, “alongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts,” bluebird adjusted its submission timing to late 2022.

On this news, bluebird’s stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.

If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased bluebird securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/bluebirdbioinc-blue-shareholder-class-action-lawsuit-stock-fraud-361/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected]

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Matthew E. Guarnero

Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/blue-investor-alert-bernstein-liebhard-llp-announces-that-a-securities-class-action-lawsuit-has-been-filed-against-bluebird-bio-inc-301230539.html

SOURCE Bernstein Liebhard LLP

SHANGHAI
, Feb. 18, 2021 /PRNewswire/ — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today the appointment of Kevin Guo as Chief Commercial Officer. Mr. Guo brings more than 22 years of commercial leadership and business management experience across a number of multinational pharmaceutical companies.

“Mr. Guo’s successful track record of commercial planning and execution for global pharmaceutical companies and his strong cross-cultural leadership skills make him uniquely suited for this important executive position at Everest Medicines,” said Kerry Blanchard, MD, PhD, chief executive officer of Everest Medicines. “He will play a critical role in ushering Everest Medicines into its next stage of growth as a commercial organization and we are excited to welcome him at this pivotal juncture.”

“I am thrilled to join Everest Medicines during this exciting period of growth. With a number of significant late-stage clinical and regulatory milestones expected across the Company’s pipeline this year, I am excited to help bring to life Everest’s important mission to bring pharmaceutical innovation to patients in China and other parts of Asia,” commented Mr. Guo.

Mr. Guo joins Everest Medicines after holding leadership positions at Eisai, where he most recently served as vice president and deputy global brand lead for LENVIMA, driving the development and execution of global product launch strategies, including in markets such as China, Japan and other Asia regions. Prior to this, he was vice president and head of the pharmaceutical business division of Eisai China Inc., where he managed several key business functions and was also appointed as chairman of the Board and president of Eisai (Suzhou) Trading Co., Ltd.. In addition, Mr. Guo was the vice president of Oncology Business Unit 1 in Shanghai Roche Pharmaceutical Ltd., among other key commercial and business development positions at prominent global pharmaceutical companies, including GlaxoSmithKline plc, Wyeth Pharmaceuticals Co., Ltd. (now part of Pfizer Inc.), Sino-American Shanghai Squibb Pharmaceutical Limited and Eli Lilly Asia Inc.. Mr. Guo obtained his Bachelor’s degree in clinical medicine from Fourth Military University in China and his Executive MBA from China Europe International Business School.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eight potentially global first-in-class or best-in-class molecules, many of which are in late stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases. For more information, please visit its website at www.everestmedicines.com. 

View original content:http://www.prnewswire.com/news-releases/everest-medicines-appoints-kevin-guo-as-chief-commercial-officer-301230556.html

SOURCE Everest Medicines

(TSXV: HAPB)

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ – Hapbee Technologies, Inc. (TSXV: HAPB) (“Hapbee“ or the “Company“), a wellness technology company utilizing groundbreaking magnetic field technology in its Hapbee wearable, is pleased to announce that it has granted stock options, exercisable to purchase up to an aggregate of 600,000 shares of the Company, to a certain consultant pursuant to the Company’s stock option plan (the “Plan“).  The options are exercisable at the price of C$0.80 per share until February 17, 2022, subject to any earlier termination in accordance with the Plan.

About Hapbee

Hapbee is a wearable magnetic field technology company that aims to help people choose how they feel. Powered by patented ultra-low Radio Frequency Energy (ulRFE^®) technology invented and licensed by EMulate Therapeutics, Inc., Hapbee delivers low-power electromagnetic signals designed to produce sensations such as Happy, Alert, Focus, Relax, Calm and Sleepy.

You can learn more about how Hapbee works at www.hapbee.com/science.

Forward-Looking Information Disclaimer

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Any statements about the size and growth rate of markets or sectors, Hapbee’s business plans, e-commerce strategies or its upcoming development targets are all forward-looking information. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including, anticipated costs, and the ability to achieve its goals.

Factors that could cause the actual results to differ materially from those in the forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, and general economic, market or business conditions, changes in legislation and regulations, increase in operating costs, equipment failures, failure of counterparties to perform their contractual obligations, litigation, the loss of key directors, employees, advisors or consultants and fees charged by service providers. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. These risks, uncertainties and assumptions include, but are not limited to, those described in Hapbee’s prospectus dated October 26, 2020, a copy of which is available on SEDAR at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

This news release contains information obtained by the Company from third parties. The Company believes such information to be accurate but has not independently verified such information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hapbee-announces-option-grant-301230555.html

SOURCE Hapbee Technologies Inc.

SHANGHAI, Feb. 17, 2021 /PRNewswire/ — Qiming’s portfolio company New Horizon Health (SEHK:6606) officially listed on the Main Board of Hong Kong Stock Exchange (HKEx) today. This is the first listed Chinese cancer early screening company.

The issue price is HK$26.66 per share; the stock opens at HK$76 per share, up 185.07%, with a market cap of HK$31.764 billion. New Horizon Health public offering shares were oversubscribed for 4,133 times with over HK$850 billion committed, making it the second most oversubscribed stock in the HKEx history.

New Horizon Health’s listing is the second IPO in our portfolio this year, and the 14th public listing in the past 13 months.

Qiming started investing in New Horizon Health since its Series B round and followed on in all subsequent funding rounds. Qiming owns 8.59% of the company after the IPO.

Founded in 2015, New Horizon Health is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The company’s vision is to prevent and cure cancer by screening and early detection. The company markets its tests through multiple channels, including hospitals, health checkup centers, insurance companies, pharmacy and online channels. The company has built a portfolio of 71 patents and patent applications globally.

New Horizon Health’s two approved cancer screening tests, Pupu Tube and ColoClear, address target populations with various risk levels.

ColoClear, the company’s proprietary, non-invasive, multi-target, FIT-DNA test, is the first and only molecular cancer screening test in China approved by NMPA. ColoClear targets a 120 million high-risk colorectal cancer population in China.

Pupu Tube, the company’s proprietary, non-invasive, stool-based FIT test, is the first self-conducted FIT screening product approved by NMPA. Pupu Tube targets a market of 633 million population (2019) recommended for colorectal cancer screening.

Additionally, New Horizon Health has two late-stage product candidates for gastric and cervical cancer screening – UU Tube and CerviClear. UU Tube is a stool-based self-conducted screening test for gastric cancer. CerviClear is a non-invasive urine-based home-use screening test for cervical cancer.

The company has built a proprietary and extensive database of Asian-specific colorectal cancer methylation profiles. The company’s multi-parameter risk assessment algorithm is the first and only one for cancer screening in China.

“New Horizon will address the big unmet cancer screening demands in China, and early detection will hopefully increase survival rate for cancer patients. The market size in China is expected to exceed 150 billion yuan. As an early market entrant, New Horizon Health has overcome regulatory and operational barriers with strong R&D and clinical capacities,” said Nisa Leung, Managing Partner of Qiming Venture Partners.

“Qiming is optimistic about the market, and we funded the company in multiple rounds. We expect to see the company contributing to lower cancer incidences, higher patients’ survival rates, and potentially benefiting global users.”

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with $5.9 billion in assets under management. Since our establishment, we have invested in outstanding companies in the TMT and healthcare industries at the early and growth stages.

Since our debut, we have backed over 380 fast-growing and innovative companies. Over 130 companies are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange and Shenzhen Stock Exchange, or achieved exit through M&A and other means. There are also over 40 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many others.

View original content:http://www.prnewswire.com/news-releases/first-cancer-early-screening-company-listed-on-hkex-as-new-horizon-health-debuts-301230549.html

SOURCE Qiming Venture Partners

VANCOUVER, BC and HOUSTON, Feb. 17, 2021 /PRNewswire/ – ESSA Pharma Inc. (“ESSA”, or the “Company”) (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 4,830,918 common shares at a public offering price of $27.00 per share, before underwriting discounts, for an aggregate offering of approximately $130.4 million (the “Offering”). ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 724,637 shares of its common shares (the “Option”). The proceeds to ESSA from the Offering are expected to be approximately $121.6 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the Option. ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. All common shares to be sold in the Offering will be offered by ESSA.

Jefferies and Piper Sandler are acting as joint book-running managers for the Offering. Oppenheimer & Co. is acting as lead manager for the Offering and Bloom Burton Securities Inc. is acting as co-manager for the Offering.

The securities described above are being offered by ESSA in the United States pursuant to a shelf registration statement on Form S-3 (File No. 333-250971) that was previously filed by ESSA with the Securities and Exchange Commission (the “SEC”) and became effective on December 29, 2020 and in Canada pursuant to ESSA’s Canadian short form base shelf prospectus (the “Canadian Base Shelf Prospectus”) dated August 24, 2020 that was previously filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario.

A preliminary prospectus supplement related to the Offering was filed with the SEC on February 16, 2021 and is available on the SEC’s website at http://www.sec.gov and a final prospectus supplement related to the Offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. A preliminary prospectus supplement to ESSA’s Canadian Base Shelf Prospectus was also filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario on February 16, 2021 and is available at http://www.sedar.com and a final prospectus related to the Offering will be filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta and Ontario and will be available at http://www.sedar.com. Copies of the final prospectus supplements related to the Offering and the accompanying prospectuses can be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by e-mail at [email protected] or by telephone at (877) 547-6340; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at [email protected].

The Company has applied to list the common shares sold under the Offering on the Nasdaq Capital Market. The Offering is expected to close on or about February 22, 2021, subject to customary closing conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients suffering from prostate cancer.

Forward-Looking Statement Disclaimer               
This release contains certain information which, as presented, constitutes “forward-looking information” within the meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance, containing words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions and includes, but is not limited to, statements regarding our expectations of the Offering, the exercise of the Option, the closing of the Offering, the anticipated use of proceeds from the Offering, and other information that is not historical information.

Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA’s actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements reflect ESSA’s current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA’s financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; (iv) general business, market and economic conditions; and (v) the satisfaction of customary closing conditions related to the proposed Offering.

Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA’s Annual Report on Form 10-K dated December 15, 2020 under the heading “Risk Factors”, a copy of which is available on ESSA’s profile on the SEDAR website at www.sedar.com, and on ESSA’s profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA’s SEDAR and EDGAR profiles. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

View original content:http://www.prnewswire.com/news-releases/essa-pharma-announces-pricing-of-public-offering-of-common-shares-301230543.html

SOURCE ESSA Pharma Inc